More MS news articles for Jan 2002

Researchers study usefulness of anti-herpes therapy in MS patients

January 9, 2002

Treatment with GlaxoSmithKline Plc’s Valtrex (valacyclovir) does not reduce the formation of active lesions in patients with relapsing-remitting MS, according to new research.

In the analysis, 70 patients were treated with either Valtrex or placebo three times a day for 24 weeks.

The study was limited to patients who had two or more MS relapses in the two-year period before study enrollment.

The average number of new active lesions per patient during 24 weeks of treatment with Valtrex was 11.9 and that during placebo treatment was 14.5.

Researchers also conducted an additional analysis by stratifying patients according to disease activity at the beginning of the study.

In that analysis, they found that patients with high levels of disease activity in the Valtrex treatment group developed fewer new active lesions per brain scan than did those in the placebo treatment group.

The median number of active lesions was also lower in the Valtrex treatment group than in the placebo treatment group.

Study findings appear in the Jan. 8 issue of Neurology.

(c) 2001 Spotlight Health